Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2013 4
2014 6
2015 6
2016 12
2017 12
2018 5
2019 4
2020 7
2021 1
2022 10
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
[89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models.
Gallegos CA, Lu Y, Clements JC, Song PN, Lynch SE, Mascioni A, Jia F, Hartman YE, Massicano AVF, Houson HA, Lapi SE, Warram JM, Markert JM, Sorace AG. Gallegos CA, et al. Theranostics. 2024 Jan 1;14(3):911-923. doi: 10.7150/thno.89206. eCollection 2024. Theranostics. 2024. PMID: 38250045 Free PMC article.
The objective of this study is to evaluate the effects of combination immunotherapy on early CD8(+) cell infiltration and its association with long term response in orthotopic syngeneic glioblastoma models. Methods: Luciferase positive GBM orthotopic mouse models (GSC005-l …
The objective of this study is to evaluate the effects of combination immunotherapy on early CD8(+) cell infiltration and its association wi …
RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.
Ye Y, Maroney KJ, Wiener HW, Mamaeva OA, Junkins AD, Burkholder GA, Sudenga SL, Khushman M, Al Diffalha S, Bansal A, Shrestha S. Ye Y, et al. Ann Med. 2023 Dec;55(1):2199366. doi: 10.1080/07853890.2023.2199366. Ann Med. 2023. PMID: 37177979 Free PMC article.
We identified a core of upregulated genes (IL4, CD40LG, ICAM2, HLA-I (HLA-A, HLA-C) and HLA-II (HLA-DQA1, HLA-DRB5) in the non-recurrent SCCA tissue enriching to the gene ontology term 'allograft rejection', which suggests a CD4+ T cell driven immune response. ...
We identified a core of upregulated genes (IL4, CD40LG, ICAM2, HLA-I (HLA-A, HLA-C) and HLA-II (HLA-DQA1, HLA-DRB5) in the non-recurrent SCC …
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells.
Shah M, Kumar H, Qiu S, Li H, Harris M, He J, Abraham A, Crossman DK, Paterson A, Welner RS, Bhatia R. Shah M, et al. JCI Insight. 2023 Jan 10;8(1):e157421. doi: 10.1172/jci.insight.157421. JCI Insight. 2023. PMID: 36413413 Free PMC article.
Despite the efficacy of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), malignant long-term hematopoietic stem cells (LT-HSCs) persist as a source of relapse. ...Here, using a transgenic CML mouse model, we found that long-term engraftment and l …
Despite the efficacy of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), malignant long-term hematopoietic stem c …
89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model.
Stone LD, Massicano AVF, Stevens TM, Warram JM, Morlandt AB, Lapi SE, Amm HM. Stone LD, et al. Sci Rep. 2022 Nov 10;12(1):19187. doi: 10.1038/s41598-022-23531-z. Sci Rep. 2022. PMID: 36357495 Free PMC article.
Accurate assessment of tumor margins with specific, non-invasive imaging would result in the preservation of healthy tissue and improve long-term local tumor control, thereby reducing the risk of recurrence. ...
Accurate assessment of tumor margins with specific, non-invasive imaging would result in the preservation of healthy tissue and improve long …
Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study.
Onuoha E, Smith AD, Cannon R, Khushman M, Kim H. Onuoha E, et al. J Gastrointest Cancer. 2023 Sep;54(3):776-781. doi: 10.1007/s12029-022-00858-4. Epub 2022 Aug 28. J Gastrointest Cancer. 2023. PMID: 36030519 Free PMC article.
PURPOSE: To investigate whether the early perfusion change in hepatocellular carcinoma (HCC) predicts the long-term therapeutic response to atezolizumab plus bevacizumab. METHODS: We retrospectively selected 19 subjects (median age: 62 years, 4 females, and 15 males) havin …
PURPOSE: To investigate whether the early perfusion change in hepatocellular carcinoma (HCC) predicts the long-term therapeutic respo …
Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line.
Hassani I, Anbiah B, Kuhlers P, Habbit NL, Ahmed B, Heslin MJ, Mobley JA, Greene MW, Lipke EA. Hassani I, et al. Biofabrication. 2022 Jul 5;14(4):10.1088/1758-5090/ac73b6. doi: 10.1088/1758-5090/ac73b6. Biofabrication. 2022. PMID: 35617932 Free PMC article.
Tumor cell subpopulations, including human cancer and mouse stromal cells, are maintained in long-term culture (29 days); cellular subpopulations increase ratiometrically over time. ...
Tumor cell subpopulations, including human cancer and mouse stromal cells, are maintained in long-term culture (29 days); cellular su …
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.
Bownes LV, Marayati R, Quinn CH, Beierle AM, Hutchins SC, Julson JR, Erwin MH, Stewart JE, Mroczek-Musulman E, Ohlmeyer M, Aye JM, Yoon KJ, Beierle EA. Bownes LV, et al. Cancers (Basel). 2022 Apr 13;14(8):1952. doi: 10.3390/cancers14081952. Cancers (Basel). 2022. PMID: 35454859 Free PMC article.
We wished to investigate the effects of two novel PP2A activators, ATUX-792 (792) and DBK-1154 (1154). METHODS: Long-term passage neuroblastoma cell lines and human neuroblastoma patient-derived xenograft (PDX) cells were used. ...
We wished to investigate the effects of two novel PP2A activators, ATUX-792 (792) and DBK-1154 (1154). METHODS: Long-term passage neu …
Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.
Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, Heinzman K, Lapi SE, Yang ES, Sorace AG. Song PN, et al. Cancers (Basel). 2022 Feb 17;14(4):1015. doi: 10.3390/cancers14041015. Cancers (Basel). 2022. PMID: 35205763 Free PMC article.
In vivo, trastuzumab prior to fractionated radiation significantly reduced hypoxia, as detected through decreased [(18)F]-FMISO SUV, synergistically improving long-term tumor response. Significant changes in IL-2, IFN-gamma, and THBS-4 were observed in combination-treated …
In vivo, trastuzumab prior to fractionated radiation significantly reduced hypoxia, as detected through decreased [(18)F]-FMISO SUV, synergi …
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy.
Quinn CH, Beierle AM, Hutchins SC, Marayati R, Bownes LV, Stewart JE, Markert HR, Erwin MH, Aye JM, Yoon KJ, Friedman GK, Willey CD, Markert JM, Beierle EA. Quinn CH, et al. Cancers (Basel). 2022 Feb 1;14(3):762. doi: 10.3390/cancers14030762. Cancers (Basel). 2022. PMID: 35159029 Free PMC article.
Current treatment options for neuroblastoma remain suboptimal as they often have significant toxicities, are associated with long-term side effects, and result in disease relapse in over half of children with high-risk disease. ...Our group has previously shown that M002, …
Current treatment options for neuroblastoma remain suboptimal as they often have significant toxicities, are associated with long-term …
61 results